Objective:

To establish the effectiveness of tibolone in menopausal symptoms and sexual function, as well as the incidence of adverse effects, in postmenopausal women.

Material and methods:

Quasi-experimental study, before-after; in 127 postmenopausal women older than 40 years, with climacteric symptoms and last menstrual period at least 2 years before entering the study, with a stable partner. In a private university clinic in Armenia (Quindío), Colombia, between 2012 and 2015. The Quality of Life Scale Menopause Rating Scale (MRS) and the Female Sexual Function Index (IFSF) were used as instruments. Simple random sampling was done. The Stata® 16.1 program was used.

Results:

The average age was 56.91 ± 7.34 years. At the end of the study, an improvement in menopausal symptoms of 94.48% (. < 0.05) was achieved, with a decrease in the MRS score from 15.91 ± 3.21 to 6.18 ± 3, 75 points (. < 0.05). Sexual dysfunctions reported an improvement of 86.56%; the IFSF went from 23.19 ± 6.41 points to 28.02 ± 6.63 (. < 0.05). Adverse effects were present from the first 3 months of initiation of therapy, the most frequent being: amenorrhea (85.82%), mastalgia (18.89%), and edema (17.32%).

Conclusions:

Tibolone has a positive effectiveness in the treatment of the symptoms of menopause, reducing both the amount and the severity of the same; associated with a clear improvement in sexual function, with mild, tolerable and transitory adverse effects.

        · resumen en Español     · texto en Español | Inglés     · Español ( pdf ) | Inglés ( pdf )